BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR-3.2%
5Y CAGR-17.9%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-3.2%/yr
vs -25.7%/yr prior
5Y CAGR
-17.9%/yr
Recent acceleration
Acceleration
+22.5pp
Accelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 31.01% |
| 2024 | 24.42% |
| 2023 | 34.21% |
| 2022 | 34.13% |
| 2021 | 74.91% |
| 2020 | 82.99% |
| 2019 | 25.77% |
| 2018 | 111.83% |
| 2017 | 23.82% |
| 2016 | -13.75% |